Wide range of phenotypic severity in individuals with late truncations unique to the predominant CDKL5 transcript in the brain
- 7 August 2022
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (12) , 3516-3524
Abstract
Cyclin‐dependent kinase‐like 5 (CDKL5) deficiency disorder (CDD) is caused by heterozygous or hemizygous variants in CDKL5 and is characterized by refractory epilepsy, cognitive and motor impairments, and cerebral visual impairment. CDKL5 has multiple transcripts, of which the longest transcripts, NM_003159 and NM_001037343, have been used historically in clinical laboratory testing. However, the transcript NM_001323289 is the most highly expressed in brain and contains 170 nucleotides at the 3′ end of its last exon that are noncoding in other transcripts. Two truncating variants in this region have been reported in association with a CDD phenotype. To clarify the significance and range of phenotypes associated with late truncating variants in this region of the predominant transcript in the brain, we report detailed information on two individuals, updated clinical information on a third individual, and a summary of published and unpublished individuals reported in ClinVar. The two new individuals (one male and one female) each had a relatively mild clinical presentation including periods of pharmaco‐responsive epilepsy, independent walking and limited purposeful communication skills. A previously reported male continued to have a severe phenotype. Overall, variants in this region demonstrate a range of clinical severity consistent with reports in CDD but with the potential for milder presentation.Keywords
Funding Information
- Chan Zuckerberg Initiative
- Child Neurology Foundation
- International Foundation for CDKL5 Research
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Eye Institute
- National Human Genome Research Institute
- Burroughs Wellcome Fund
- National Institutes of Health (DP5OD26428, U01HG007709)
This publication has 26 references indexed in Scilit:
- Characterisation of CDKL5 Transcript Isoforms in Human and MousePLOS ONE, 2016
- There is variability in the attainment of developmental milestones in the CDKL5 disorderJournal of Neurodevelopmental Disorders, 2015
- The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathyEuropean Journal of Human Genetics, 2012
- CDKL5 alterations lead to early epileptic encephalopathy in both gendersEpilepsia, 2011
- A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brainHuman Genetics, 2011
- Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 geneAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009
- Mutational spectrum of CDKL5 in early‐onset encephalopathies: a study of a large collection of French patients and review of the literatureClinical Genetics, 2009
- The three stages of epilepsy in patients with CDKL5 mutationsEpilepsia, 2008
- Mutations of CDKL5 Cause a Severe Neurodevelopmental Disorder with Infantile Spasms and Mental RetardationThe American Journal of Human Genetics, 2004
- Mutations in the X-Linked Cyclin-Dependent Kinase–Like 5 (CDKL5/STK9) Gene Are Associated with Severe Neurodevelopmental RetardationThe American Journal of Human Genetics, 2004